On July 28th, the Chair of US$1.4 BILLION market cap Bellus Health (BLU)'s Clinical Advisory Board Dr. Jacky Smith said regarding Algernon Pharmaceuticals (CSE: AGN)'s Phase 2 study of Ifenprodil for chronic cough, "This additional analysis confirms my initial positive impression of the study. The NMDA receptor has always been an interesting target for cough, but other agents have been poorly tolerated. To see effects of this magnitude in an IPF population, where other drugs have failed to demonstrate a benefit, is notable, and I look forward to seeing the Company’s full data set next month."
The full data set could be released by AGN at any time now!
AGN competitor Trevi Therapeutics (TRVI) announced today that they are hosting a Virtual R&D Day on September 19th and TRVI's featured guest will be Dr. Peter Dicpinigaitis, MD, Professor of Medicine, Albert Einstein College of Medicine.
Earlier this month, Dr. Peter Dicpinigaitis said that AGN's Ifenprodil could be a "first-in-class" chronic cough treatment!
The two top chronic cough doctors that BLU and TRVI rely on for expertise are both paying very close attention to AGN!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.